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Abstract
Background: Inhibin is a tumor-suppressor and activin antagonist. Inhibin-deficient mice develop gonadal tumors 
and a cachexia wasting syndrome due to enhanced activin signaling. Because activins signal through SMAD2 and 
SMAD3 in vitro and loss of SMAD3 attenuates ovarian tumor development in inhibin-deficient females, we sought to 
determine the role of SMAD2 in the development of ovarian tumors originating from the granulosa cell lineage.
Methods: Using an inhibin α null mouse model and a conditional knockout strategy, double conditional knockout 
mice of Smad2 and inhibin alpha were generated in the current study. The survival rate and development of gonadal 
tumors and the accompanying cachexia wasting syndrome were monitored.
Results: Nearly identical to the controls, the Smad2 and inhibin alpha double knockout mice succumbed to weight 
loss, aggressive tumor progression, and death. Furthermore, elevated activin levels and activin-induced pathologies in 
the liver and stomach characteristic of inhibin deficiency were also observed in these mice. Our results indicate that 
SMAD2 ablation does not protect inhibin-deficient females from the development of ovarian tumors or the cachexia 
wasting syndrome.
Conclusions: SMAD2 is not required for mediating tumorigenic signals of activin in ovarian tumor development 
caused by loss of inhibin.
Background
The transforming growth factor β (TGFβ) superfamily
ligands including activins and inhibins play integral roles
in a wide variety of developmental processes [1-3]. Inhib-
ins are α and β subunit heterodimers (inhibin A: α, βA;
inhibin B: α, βB) that oppose activin signaling by antago-
nizing activin receptors (ACVRs), whereas activins are
homodimers (activin A, βA: βA; activin B, βB: βB) or het-
erodimers (activin AB, βA: βB) of the β subunits [4-6].
Activin signal transduction is initiated when the ligand
binds to its type 2 serine/threonine kinase receptor which
in turn phosphorylates the type 1 receptor [7-11]. The
type 1 receptor then phosphorylates and activates recep-
tor-regulated SMADs (R-SMADs; SMAD2 and SMAD3),
which subsequently form complexes with the common
SMAD, SMAD4. The R-SMADs/SMAD4 can translocate
into the nucleus to regulate gene expression via recruit-
ment of specific transcription factors, activators, and
repressors [12-15].
Activins and inhibins are expressed in ovarian granu-
losa cells and were first described for their roles in FSH
regulation [16,17]. However, subsequent studies demon-
strated the involvement of these ligands in multiple
developmental and pathological events including car-
cinogenesis [18-20]. Inhibin is a tumor suppressor [21], as
inhibin α (Inha) null mice develop gonadal sex cord-
stromal tumors originating from the granulosa/Sertoli
cell lineages [21], presumably due to the loss of activin
antagonism. The tumors secrete an excessive amount of
activins that signal through activin receptor type 2
(ACVR2) in the stomach and liver, leading to a cachexia
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wasting syndrome and pathological changes in these
organs (depletion of parietal cells in the glandular stom-
ach and hepatocellular death in the liver) [22,23]. Lethal-
ity in Inha null mice is primarily caused by the cachexia
wasting syndrome characterized by weight loss, lethargy,
and anemia [24]. Although the mechanisms of tumori-
genesis in Inha  null mice are not fully understood,
activin, FSH, and estradiol may play pivotal roles in the
development of gonadal tumors [25-28]. As absence of an
α subunit precludes α:β dimer assembly, activin is highly
elevated in Inha null mice due to the ability of the β sub-
units to only form β:β activin dimers [24]. While activin-
deficient mice die after birth due to craniofacial defects
[9], accumulating evidence suggest that activins play
important roles in gonadal tumor development in
inhibin-deficient mice. Expression of the activin βA sub-
unit is elevated in the gonads of inhibin-deficient mice
[29]. Moreover, tumorigenesis is attenuated in inhibin-
deficient mice that transgenically express follistatin, an
activin antagonist [30,31]. More recently, we demon-
strated that administration of a chimeric ACVR2 ectodo-
main (ActRII-mFc), a known activin antagonist, delayed
gonadal tumorigenesis in inhibin-deficient mice [32].
To dissect the activin downstream signaling compo-
nents during ovarian tumorigenesis, we previously gener-
ated Inha/Smad3 double knockout mice in which females
are substantially, but not completely, protected from the
development of ovarian tumors and the accompanying
cachexia syndrome [28]. Since SMAD2 and SMAD3 are
activin signal-transducers in vitro and the gonadal
somatic cells (granulosa cells and Sertoli cells) from
which inhibin-deficient tumors are derived express both
SMADs, we hypothesized that SMAD2 may partially
compensate for the loss of SMAD3 in mediating ovarian
activin signals in the Inha/Smad3  double knockout
females. To circumvent the embryonic lethality of Smad2
ubiquitous knockout [33-35], we conditionally deleted
Smad2 in ovarian granulosa cells null for Inha to deter-
mine the role of SMAD2 in gonadal tumor development.
Methods
Generation of Inha/Smad2 conditional knockout mice
Mice used in this study were maintained on a mixed
C57BL/6/129S6/SvEv background and manipulated
according to the NIH Guide for the Care and Use of Labo-
ratory Animals. Generation of the Inha null mice and the
Smad2 null allele was described previously [21,36]. The
Smad2  conditional allele was constructed by flanking
exons 9 and 10 with two loxP sites using the Cre-LoxP
system as previously documented [37,38]. The Amhr2cre/+
mice were produced via insertion of a Cre-Neo cassette
into the fifth exon of the anti-Mullerian hormone recep-
tor type 2 (Amhr2) locus [39]. Generation of the
Smad2flox/-; Inha-/-; Amhr2cre/+ mice (experimental group)
and Smad2flox/-; Inha-/- mice (control group) is depicted in
Figure 1.
Genotyping analysis
Genotyping of the mice was performed by PCR using
genomic tail DNA. Table 1 lists the primer sequences uti-
lized in the PCR assays. The annealing temperatures for
Inha, Amhr2cre/+, and Smad2 were 61°C, 62°C, and 60°C,
respectively. The resultant PCR products were separated
and visualized on 1% agarose gels.
Measurement of body weight and generation of survival 
curve
Body weights of animals were measured and recorded
weekly from ages 4-26 weeks, and the mice were closely
monitored for the development of the cachexia wasting
syndrome (i.e., weight loss, kyphoscoliosis, and lethargy)
[24]. Mice were sacrificed when their body weights fell
below 15 grams or when other severe cachexia symptoms
developed as described elsewhere [24,40]. All mice were
sacrificed at the end of 26 weeks for a final analysis. To
determine the potential effect of conditional deletion of
Smad2 on ovarian tumor development at early stages, the
Inha/Smad2  cKO mice were also examined at 4 to 9
weeks of age.
Histological analysis
Mice were anesthetized by isoflurane inhalation at the
time of sacrifice. A small portion of the tails were cut and
stored at -70 °C for subsequent genotype verification.
Ovaries, stomachs, and livers were removed from the
mice and fixed in 10% (vol/vol) neutral buffered formalin
overnight. The fixed samples were washed with 70% etha-
nol prior to paraffin embedding. Ovaries were sectioned
and stained with periodic acid-Schiff (PAS)-hematoxylin,
whereas livers and stomachs were processed for hema-
toxylin and eosin (HE) staining. All staining procedures
were conducted in the Pathology Core Services Facility at
Baylor College of Medicine using standard protocols.
Immunohistochemistry
Expression of SMAD2 in Smad2flox/-; Inha-/-; Amhr2cre/+
and Smad2flox/-; Inha-/- mice was determined by immuno-
histochemistry. Briefly, ovaries from 4-week-old mice
were fixed in formalin and serially sectioned (5 μm).
Antigen retrieval was performed by boiling the sections
in 10 mM citrate buffer (pH 6.0). The sections were then
blocked using 3% BSA/10% serum in PBS, and incubated
with SMAD2 primary antibody (1:100 dilution; Cell Sig-
naling). Subsequent procedures were performed using
ABC and DAB kits (Vector Lab). The sections were coun-
terstained with hematoxylin and mounted with Per-
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Activin A analysis
Blood samples were collected from anesthetized mice by
cardiac puncture upon sacrifice, placed in serum separa-
tor tubes (Becton Dickinson, Franklin Lakes, NJ, USA),
and allowed to clot at room temperature. Serum was then
i so la t ed  fr o m  t h e  b l ood  s a m p l es  b y  c e n t ri fu g a t i o n  a n d
stored at -20°C until assayed. Total serum activin A levels
were measured using a specific ELISA [41] according to
the manufacturer's instructions (Oxford Bio-Innovations,
Oxfordshire, UK) with modifications [42]. The average
intraplate coefficient of variation (CV) was 7.4% and the
interplate CV was 10.8% (n = 2 plates). The limit of detec-
tion was 0.01 ng/ml.
Statistical analyses
Differences among groups (average ovary weight, liver
weight, and serum activin A levels) were assessed using
one-way ANOVA followed by a Kruskal-Wallis post-hoc
test. The survival curve was analyzed using a logrank test.
For all analyses, significance was defined at P < 0.05. Data
are reported as mean standard error of the mean (SEM).
Results
Generation of Smad2flox/-; Inha-/-; Amhr2cre/+ mice
To understand the roles of SMAD2 in ovarian tumor
development in inhibin-deficient mice, we took advan-
tage of a conditional knockout strategy to disrupt the
Smad2 gene in mouse ovarian granulosa cells. To over-
come the embryonic lethality phenotype resulting from
Smad2  ubiquitous deletion, a Smad2  floxed allele was
generated by flanking exons 9 and 10 of the Smad2 gene
with 2 loxP sites [37]. The Amhr2cre/+ knock-in mouse line
validated in our previous studies to delete genes
expressed in ovarian granulosa cells [38,43-47] was uti-
Figure 1 Generation of Inha/Smad2 cKO mice. (A) Smad2flox/+; Inha+/- mice were mated with Smad2flox/flox mice to produce Smad2flox/flox; Inha+/- 
mice, and Smad2+/- mice were mated with Inha+/-; Amhr2cre/+ mice to generate Smad2+/-; Inha+/-; Amhr2cre/+ mice. These mice were then crossed to 
produce Smad2flox/-; Inha-/-; Amhr2cre/+ mice (experimental group) and Smad2flox/-; Inha-/- mice (control group). The generation of the Inha null, Smad2 
null and Smad2 floxed alleles is described in the Materials and Methods. (B) Genotyping of mice using PCR analysis. Representative PCR images are 
shown with corresponding genotypes listed below: 1. Inhα-/-; Smad2flox/-; Amhr2+/+ ; 2. Inhα-/-; Smad2flox/-; Amhr2cre/+ ; 3. Inhα+/+; Smad2flox/+; Amhr2cre/+ 
; 4. Inhα+/-; Smad2flox/+; Amhr2cre/+; 5. Inhα+/-; Smad2flox/+; Amhr2+/+. (C) Recombination of Smad2 floxed allele in Inhα-/-; Smad2flox/-; Amhr2cre/+ tumors. Note 
that the recombined (Rec) allele of Smad2 can be detected only in the tumor tissues of the Inha/Smad2 cKO mice but not in the controls where the 
Cre recombinase is not expressed. (D and E) Immunohistochemical analysis of SMAD2 protein expression in Smad2flox/-; Inha-/-; Amhr2+/+ (D) and 
Smad2flox/-; Inha-/-; Amhr2Cre/+(E) mice. Both panels are representative images. Note the dramatic reduction of SMAD2 protein expression in the condi-
tional knockout mice vs. controls (100 × magnification).Rajanahally et al. Reproductive Biology and Endocrinology 2010, 8:69
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lized. Figure 1A depicts the breeding scheme used to gen-
erate the control (Smad2flox/-; Inha-/-) and experimental
Smad2flox/-; Inha-/-; Amhr2cre/+ (Inha/Smad2 cKO) female
mice. Representative genotype analyses are presented in
Figure 1B. We previously demonstrated that the Smad2
floxed allele can be recombined and deleted in mouse
granulosa cells in Smad2 cKO mice [38]. As a further sup-
port that inhibin-deficient tumors originate from granu-
losa cells, the Smad2  recombined allele was readily
detectable in the tumor tissues of Smad2flox/-;  Inha-/-;
Amhr2cre/+ mice, but not in the controls lacking the Cre-
recombinase (Figure 1C). Moreover, immunostaining
revealed a dramatic reduction of SMAD2 protein levels in
the granulosa cells of Smad2flox/-; Inha-/-; Amhr2cre/+ mice
vs. controls (Figure 1D and 1E).
Conditional knockout of Smad2 in inhibin-deficient mice 
does not alter lethality
To evaluate the overall effects of Smad2 conditional dele-
tion on the life span of inhibin-deficient mice, we gener-
ated and analyzed the survival curves of the Smad2flox/-;
Inha-/-  controls (n  = 19) and the Smad2flox/-;  Inha-/-;
Amhr2cre/+ (n  = 16) experimental mice (Figure 2). The
median survival was 13 weeks for both Smad2flox/-; Inha-/-
and  Smad2flox/-;Inha  -/-;  Amhr2cre/+  females. Statistical
analysis indicated that Smad2 deficiency did not alter the
lifespan of Inha null mice (P > 0.05).
Development of ovarian tumors and cachexia wasting 
syndrome in Smad2flox/-; Inha-/-; Amhr2cre/+ mice
An early sign of tumor development in Inha null mice is
severe body weight loss, a prominent feature of the
cachexia wasting syndrome. To determine if Smad2 defi-
ciency affects the development and progression of the
cachexia syndrome, the body weights of Smad2flox/-; Inha-
/- and Smad2flox/-; Inha-/-; Amhr2cre/+ mice were measured
weekly. The results showed that Smad2flox/-;  Inha-/-;
Amhr2cre/+ mice suffered from weight loss similar to that
observed in Smad2flox/-;  Inha-/- mice (data not shown).
Because the cachexia syndrome is also characterized by
distinct activin-induced pathological changes in the
stomach and liver [22,23], these organs were collected
and examined along with the gonads. The ovary and liver
weights of the wild type (WT), Smad2flox/-; Inha-/-, and
Smad2flox/-;  Inha-/-;  Amhr2cre/+  mice were measured.
Despite the marked changes of the weights of ovary and
liver in both Smad2flox/-; Inha -/- (n = 11) and Smad2flox/-;
Inha-/-; Amhr2cre/+ mice (n = 5) compared to WT mice (n
= 5; P < 0.01), no significant differences in these parame-
ters were found between the Smad2flox/-;  Inha-/-;
Amhr2cre/+ mice and the Smad2flox/-; Inha-/- controls at a
similar stage of tumor progression (P > 0.05; Figure 3).
Figure 2 Survival curve of Smad2flox/-; Inha-/- and Smad2flox/-; Inha-
/-; Amhr2Cre/+ mice. The survival of the Smad2flox/-; Inha-/- (n = 19; con-
trol group) and Smad2flox/-; Inha-/-; Amhr2Cre/+ (n = 16; experimental 
group) mice were recorded weekly during 4 to 26 weeks. The survival 
curve was generated and analyzed using a Mantel-Cox test (GraphPad 
Software, GraphPad Prism version 5.0 b for MacOS X). Statistical signif-
icance was not found between the two groups [χ2 (1, N = 35) = 0.051, 
P = 0.82].
Table 1: Primer sequences for genotyping PCR
Gene Primer sequence (5'-3')
Forward Reverse
Inha WT cct ggg tgg cgc agg ata tgg ggt ctc ctg cgg ctt tgc gc
Inha null cct ggg tgg cgc agg ata tgg gga tat gcc ctt gac tat aat g
Amhr2cre cgc att gtc tga gta ggt gt gaa acg cag ctc ggc cag c
Smad2 flox tac ttg ggg caa tct ttt cg gtc act ccc tga acc tga ag
Smad2 null gct gag tgc cta agt gat agt gca tct tct ttt tcc ccg ctg g
Smad2 Rec gag ctg cgc aga cct tgt tac gtc act ccc tga acc tga ag
Rec, recombined floxed alleleRajanahally et al. Reproductive Biology and Endocrinology 2010, 8:69
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Histological analyses were performed on the ovaries
and livers of WT, Smad2flox/-;  Inha-/-, and Smad2flox/-;
Inha-/-; Amhr2cre/+mice. We first examined the histology
of ovaries and livers of the Smad2flox/-; Inha-/-; Amhr2cre/
+mice and the Smad2flox/-;  Inha-/-  mice at the same
advanced tumor stage when severe cachexia was
observed. In the absence of inhibins, ovarian tumors were
grossly hemorrhagic and contained blood-filled cysts
irrespective of the status of SMAD2 (Figure 4B and 4C).
Microscopic analysis of the livers demonstrated hepato-
cellular death and lymphocyte infiltration around the
central vein (Figure 4E and 4F), another activin-induced
pathological effect [22,24]. Furthermore, glandular stom-
achs of both the control and experimental groups were
characterized by depletion of eosinophilic parietal cells
and glandular atrophy (Figure 4H and 4I). The observed
liver and stomach pathologies are consistent with those of
cachectic inhibin-deficient mice [24].
Next, to uncover potential effect of Smad2 deletion on
ovarian tumor development at an early stage, we exam-
ined the tumor status in the Smad2flox/-; Inha-/-; Amhr2cre/
+ mice at various time points between 4 and 9 weeks of
age, since inhibin-deficient mice can develop tumors as
early as 4 weeks. At 4 weeks of age, significant differences
were not found in either the cachexia syndrome associ-
ated parameters (ovary and liver weights) or tumor his-
tology between the controls (n = 3) and the Smad2flox/-;
Inha-/-; Amhr2cre/+ (n = 3) mice (P > 0.05). Similar results
were obtained when comparisons were performed at
both 6 weeks (n = 3 for each group) and 8-9 weeks of age
(n = 3 for each group) (data not shown). Thus, condi-
tional deletion of Smad2 does not delay ovarian tumor
development and the progression of the cachexia wasting
syndrome in inhibin-deficient mice.
Activin levels
Serum activins are elevated in the inhibin-deficient mice
due to the excessive production of the β subunits from
gonadal tumors [24]. Thus, activin levels correlate with
the tumor status in mice lacking inhibin. The superphysi-
ological level of activins is the primary cause of the
cachexia syndrome [22,24]. Since both Smad2flox/-; Inha-/-
and  Smad2flox/-;  Inha-/-;  Amhr2cre/+  mice displayed the
severe cachexia syndrome, and ovarian tumors in these
mice were histologically indistinguishable, we proposed
that conditional deletion of Smad2 does not alter the pro-
duction of activins, an indicator of tumor status in mice
lacking inhibins. To test this hypothesis, we measured
activin A levels in Smad2flox/-;  Inha-/-;  Amhr2cre/+ mice
and the corresponding control mice at the advanced
tumor stage, and found that levels of activin A were simi-
larly elevated in both Smad2flox/-; Inha-/- control (n = 11;
54.1 ± 8.2 ng/ml) and Smad2flox/-;  Inha-/-;  Amhr2cre/+
experimental females (n = 5; 47.0 ± 6.7 ng/ml) (P > 0.05)
in comparison to WT females (n = 7; 0.1 ± 0.0 ng/ml).
Discussion
The aim of the current study was to define the role of
SMAD2 in the development of ovarian tumors and
activin-induced cancer cachexia syndrome. We demon-
strated that conditional deletion of SMAD2 did not pre-
vent the inhibin-deficient females from ovarian
tumorigenesis and death; all Inha/Smad2  cKO mice
developed sex cord-stromal tumors resembling those
observed in Inha  null mice. Furthermore, Inha/Smad2
Figure 3 Ovary and liver weights of WT, Smad2flox/-; Inha-/- control 
(Con) and Smad2flox/-; Inha-/-; Amhr2cre/+(S2/Inha cKO) experimen-
tal mice. Note the dramatic alteration of the weights of the ovary and 
liver of the Smad2flox/-; Inha-/- (6-26 wk; n = 11) and Smad2flox/-; Inha-/-; 
Amhrcre/+(6-23 wk; n = 5) mice compared to adult WT mice (12 wk; n = 
5) due to tumor development. However, no differences in the ovary 
and liver weights were observed between the control and S2/Inha cKO 
mice. All data are shown as mean ± SEM, and bars without a common 
letter are significantly different at P < 0.01.Rajanahally et al. Reproductive Biology and Endocrinology 2010, 8:69
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cKO mice suffered from the cancer cachexia syndrome,
as evidenced by the severe weight loss and pathological
lesions in the stomach and liver (i.e., mucosal atrophy
with depletion of parietal cells in the glandular stomach
and hepatocellular necrosis around the central vein) [24].
These results indicate that SMAD2 is not required for
transducing superphysiological activin signals in the con-
text of gonadal tumor development due to loss of inhibin.
Activins play complex roles in carcinogenesis. In sev-
eral extragonadal tissues, activin A has been reported to
be an anti-tumorigenic factor. For example, activin pre-
vents cell proliferation in breast cancer through SMAD2/
3-dependent regulation of cell cycle arrest genes [48].
Similarly, activin A acts as a tumor suppressor in neuro-
blastoma cells via inhibition of angiogenesis, a key feature
of tumorigenesis. Inhibition of endothelial cell prolifera-
tion can be achieved by active forms of SMAD2 and
SMAD3, suggesting this inhibitory effect is SMAD2/3
dependent [49]. Moreover, activin A has also been
reported to prevent the proliferation of tumor cells
derived from the prostate and gall bladder [50,51].
Despite the above anti-tumorigenic effects of activins
in extragonadal tissues, activins promote tumor develop-
ment in the gonads [28,52]. The tumorigenic roles of
activins have been suggested by the Inha knockout mouse
model [21], and the inhibin-deficient mouse model has
been exploited to gain a deep understanding of the
activin signaling pathway in gonadal tumor development.
The Inha/Smad3 double knockout mice generated in our
previous study highlights the importance of activins in
Figure 4 Histological analyses of ovary, liver, and stomach from WT, control, and experimental female mice. (A) Ovarian histology of an 8 wk 
old WT mouse. The ovary contains follicles at various developmental stages. Arrows indicate granulosa cells and arrowheads denote oocytes sur-
rounded by a magenta-colored zona pellucida. (B and C) Ovarian histology of a 26 wk old Smad2flox/-; Inha-/- mouse (B) and a 23 wk old Smad2flox/-; Inha-
/-; Amhr2cre/+mouse (C), respectively. Tumors from both genotypes were bilateral, large, hemorrhagic, and histologically indistinguishable. (D-F) Histol-
ogy of livers from a 12 wk old WT mouse (D), a 15 wk old Smad2flox/-; Inha-/- mouse (E), and an 8 wk old Smad2flox/-; Inha-/-; Amhr2cre/+mouse (F). Hepa-
tocellular death around the central vein and lymphocyte infiltration are present in the livers of both the Smad2flox/-; Inha-/- control and Smad2flox/-; Inha-
/-; Amhr2cre/+mice (arrows). (G-I) Glandular stomachs from a 12 wk old WT mouse (G), a 26 wk old Smad2flox/-; Inha-/- mouse (H), and a 14 wk old Smad2flox/
-; Inha-/-; Amhr2cre/+mouse (I). Note the depletion of parietal cells in both the control and experimental mice (single asterisk) in comparison with the 
WT mouse (the large and eosinophilic cells; double asterisks). The junction ridge between the squamous epithelium of the forestomach and the glan-
dular stomach is indicated by blue arrows. Scale bars = 100 μm.Rajanahally et al. Reproductive Biology and Endocrinology 2010, 8:69
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gonadal tumorigenesis [28]. Since deletion of SMAD3
only delays ovarian tumor development in the Inha null
mice [28], we were interested in determining the poten-
tial involvement of SMAD2 in mediating the potentiated
activin signaling in ovarian tumors lacking inhibins.
SMAD2 and SMAD3 are functionally distinct proteins.
Structural differences at the MH1 domain exist between
SMAD2 and SMAD3. The extra amino acids (encoded by
exon 3) in the SMAD2 MH1 domain prevents its direct
binding to DNA, and specific transcription factors are
required for SMAD2-DNA binding [53-55]. In contrast,
SMAD3 has direct DNA-binding ability [56,57]. Addi-
tionally, SMAD3-SMAD4 signaling-dependent genes
outnumber SMAD2-SMAD4 dependent genes by more
than 4-fold, as identified in Hep3B cells in a recent
microarray experiment [58]. Finally, distinct signaling
outcomes have been identified in developing mouse Ser-
toli cells linked with developmentally regulated, differen-
tial use of SMAD2 and SMAD3 [59]. Despite these
distinctive aspects, SMAD2 and SMAD3 share more than
90% identity in their amino acid sequences [60], and
functional redundancy between these two proteins has
been demonstrated in the ovary [58,38].
Our current findings, in combination with our previous
results, indicate that SMAD2 and SMAD3 may function
redundantly to mediate gonadal tumorigenesis in
inhibin-deficient mice. In the case of conditional deletion
of  Smad2, SMAD3 compensates for the deficiency of
SMAD2 and transduces essential signals contributing to
ovarian tumor development; consequently, tumorigenesis
is not altered. On the other hand, loss of SMAD3 in the
Inha null mice attenuates but does not prevent ovarian
tumor development, suggesting that SMAD2 may par-
tially compensate for the loss of SMAD3. However, our
model does not rule out the potential involvement of
SMAD-independent signaling in inhibin-deficient ovar-
ian tumor development or the possibility that SMAD2
may not be involved in gonadal tumor development (See
Figure 5 for details). It will be interesting to further
explore if the contrasting role of activins in gonadal ver-
sus extragonadal tissues is linked to the differential
impingement of downstream SMAD2 and/or SMAD3
transducers. Furthermore, the potential crosstalk
between SMAD-dependent and SMAD-independent sig-
naling pathways in inhibin-deficient tumor development
awaits further investigation.
Conclusions
SMAD2 is not required for mediating tumorigenic sig-
nals of activin in ovarian tumor development caused by
loss of inhibin.
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Figure 5 Hypothetical working model for SMAD2/3 signaling in mediating gonadal tumorigenesis in inhibin-deficient female mice. (A) In 
the WT ovary, the signaling of activins is finely tuned by inhibins, which is important in the maintenance of normal granulosa cell function, follicular 
development, and fertility. (B) In the absence of inhibins, activin signaling is potentiated with increased production of activins by the gonads and tu-
mors due to the loss of antagonism by inhibins. Superphysiological levels of activins can signal through both SMAD2 and SMAD3 in the ovary. As 
demonstrated by the Inha/Smad3 double knockout mouse model [28], ovarian tumor development is attenuated in Inha null mice lacking SMAD3, 
implying that the function of SMAD3 is not fully compensated by SMAD2. Complementarily, the Inha/Smad2 cKO mouse model generated in the cur-
rent study suggests that SMAD3 can potentially mediate essential tumorigenic signals of activins in the Inha null mice (C). However, our model does 
not rule out the potential involvement of SMAD-independent signaling (dotted lines) in inhibin-deficient ovarian tumor development or the possibil-
ity that SMAD2 may not be involved in gonadal tumor development.Rajanahally et al. Reproductive Biology and Endocrinology 2010, 8:69
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